Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
Sacha I Rothschild Department of Internal Medicine, Medical Oncology, University Hospital Basel, Basel, Switzerland Abstract: The therapeutic landscape in non-small-cell lung cancer (NSCLC) is changing. The description of molecular alterations leading to NSCLC carcinogenesis and progression (so-ca...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-09-01
|
| Series: | Lung Cancer : Targets and Therapy |
| Online Access: | http://www.dovepress.com/clinical-potential-of-nintedanib-for-the-second-line-treatment-of-adva-peer-reviewed-article-LCTT |